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Summary Previous work has shown that the lethal effects of glucocorticoids on the human lymphoblastoid
cell line, CEM-C7, are antagonized by the simultaneous presence of 1-,B-D-arabinofuranosylcytosine (Ara-C).
A possible cell cycle mechanism prompted further studies using flow microfluorimetry. We now report that (1)
Ara-C (10-100nM) blocks cells in S-phase and (2) the block is reversible after the drug is removed. A second
treatment protocol, in which glucocorticoid is added to cells recovering from the effects of 24h exposure to
Ara-C, results in a clear synergism between the 2 drugs. This synergism is observed over a range of
concentrations (5-100nM), but is most significant at low doses, where inhibition of cell growth by Ara-C
occurs but cell killing is minimal. Prior treatment with Ara-C increases the number of cells killed in the
presence of steroid during the period 12-24h after removal of the S-phase block. Combinations of Ara-C and
steroid can thus be either synergistic or antagonistic, depending on the drug scheduling.
Glucocorticoids are an essential element in the
primary treatment of acute lymphoblastic leukaemia
(Simone, 1979), yet the precise mechanism of their
cytocidal action remains unclear. Studies of
glucocorticoid action on human leukaemic cells
based on the response of the patient to therapy, or
on cells isolated from patients who have been
treated, are now more difficult because of the
virtually universal use of the multi-drug schedules
that have proved so successful in leukaemia
therapy. As an alternative to the use of material
obtained directly from the patient, a glucocorticoid-
sensitive clone (C7) isolated from the human
leukaemic cell line CCRF-CEM (Foley et al., 1965)
has provided a suitable model system for the
investigation of glucocorticoid action on human
leukaemic cells (Norman et al., 1981).
Use of the CEM-C7 system to study cytotoxicity
in vitro has revealed interactions between
glucocorticoids and other anti-leukaemic drugs
which may be of importance clinically, and has also
provided some insight into the mechanism of
glucocorticoid action (Norman et al., 1978; Gledhill
& Norman, 1981b). One of the drugs tested was the
pyrimidine nucleoside analogue 1-fl-D-arabino-
furanosylcytosine (cytosine arabinoside, Ara-
C). When CEM-C7 cells were exposed to
prednisolone and Ara-C according to a protocol
whereby Ara-C was present during the final 24h of a
48 h incubation with the steroid, the observed
decrease in cloning efficiency was less than
predicted from the toxicity of each drug when used
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alone (Gledhill & Norman, 1981b). Furthermore,
the antagonistic interaction was still apparent when
using low concentrations of Ara-C which were
themselves non-toxic, indicating that it was Ara-c,
not prednisolone, which was responsible for the
antagonism.
One explanation of this antagonism could be that
Ara-C reversibly blocks some CEM-C7 cells in S-
phase of the cell cycle, without killing them, and
that in this state the cells are protected from the
lethal effect of steroid. Studies with Ara-C in other
cell systems have shown that the drug is capable of
inhibiting DNA synthesis without killing the cells
(Graham & Whitmore, 1970a; Preisler et al., 1979)
and that the S-phase block can be reversed after
removal of the drug (Tobey & Crissman, 1972;
Yataganas et al., 1974). We therefore wished to
determine (1) whether or not Ara-C blocked CEM-
C7 cells in S-phase, (2) whether any S-phase block
was reversible, and if so (3) whether cells released
from the block would have an increased sensitivity
to glucocorticoid-induced cell killing. A preliminary
account of part of this work has already been given
(Gledhill & Norman, 1981a).
Materials and methods
Lymphoblast culture
Glucocorticoid-sensitive CEM-C7 lymphoblastoid
cells were grown in suspension culture in medium
RPM1 1640 supplemented with 10% foetal calf
serum (Flow Laboratories). The cells could be
maintained in exponential growth at cell
concentrations between 105 and 4x 106m-1, with
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a doubling time of about 20h. Cells were counted
with a Coulter Counter, model DN (100 t orifice,
aperture current 1, Threshold 11).
Protocolsfor drug addition
Protocol I This was the original protocol used to
study the interaction of glucocorticoids with other
anti-leukaemic drugs (Norman et al., 1978). The day
before the start of each experiment, cell aliquots
were centrifuged (500g) and resuspended in fresh
medium at concentrations of 2-3 x i05ml-P. The
cells were first treated for 24h with steroid alone,
since previous studies (Harmon et al., 1979)
demonstrated a lag period of about 20h before cell
killing began. The cells were then treated for a
further 24h in the presence of steroid plus Ara-C. In
addition to an untreated control, the effects of
steroid alone and Ara-C alone were also measured.
One flask was used for each control and drug
concentration.
Protocol 2 Cells were exposed to Ara-C alone for
24h, Ara-C was removed by washing once in drug-
free medium, and the cells were resuspended in fresh
medium containing steroid for a further period of
culture. Cytosine arabinoside caused inhibition of
cell growth during 24h, so after removal of the
drug, cell concentrations in control and Ara-C
treated cultures were readjusted to the same value,
4-5 x 105 ml- '. Measurement of Ara-C induced cell
killing was made directly after treatment with the
drug.
Measurement ofviability
Plating efficiency Colony-forming ability was
measured by plating cells in agarose gels with a
feeder layer of human fibroblasts (SAL MAT)
(Norman et al., 1978). Cells were washed free of any
drugs before plating. Control cells were plated in
four 60mm dishes at a concentration of 250 per
dish or in five 35mm dishes at 100 cells per dish.
The cell density was increased by up to 10-fold in
order to ensure the growth of adequate numbers of
colonies after treatment with high concentrations of
Ara-C. Colonies were counted 12-14 days after
plating. Mean control plating efficiency in these
experiments was 45%.
Nuclear pyknosis Samples taken from cell
suspensions were mixed with an equal volume of
normal human serum, before being wet-fixed and
stained by the method of Trowell (1955). The
human serum was necessary to ensure good
adhesion of the cells to the slide. Dead cells were
recognised by their small, homogeneously-stained
pyknotic nuclei. Five hundred cells were counted on
each slide.
DNA analysis by flow microfluorimetry (Crissman
& Tobey, 1974) Cell aliquots containing 106 cells
were centrifuged and the pellets resuspended in 70%
ethanol (5ml). Fixed cells were stored at 4°C. For
DNA analysis the fixed cells were centrifuged and
resuspended in 1 ml of mithramycin stain
(50,ugml- ' mithramycin, 25mM MgCl2, 25%
ethanol). Fluorescence analysis for DNA profiles
was performed using a fluorescence-activated cell
sorter (FACS-II, Becton-Dickinson FACS Systems,
Sunnyvale, CA.). Cells were examined with the
argon-ion laser set at 180mW, 457nm and the
photomultiplier tube for fluorescence detection at
55OV. A fluorescence gain of 0.5 and a light scatter
gain of 4 was employed in all experiments. Samples
were processed at 800-1200 cells per sec and each
profile represents the accumulated data from 10,000
cells.
Results
Effects of cytosine arabinoside on the cell cycle of
CEM-C7 cells
CEM-C7 cells were incubated with Ara-C (10-
100nM) for 24h. After this time aliquots were taken
for DNA analysis by flow microfluorimetry (FMF).
In the experiments shown in Figure 1, 10nM Ara-C
caused only partial inhibition of cell growth (38%)
and had only a small effect on the FMF pattern. At
20nM there was some accumulation of cells in the
later part of S-phase. As the Ara-C concentration
increased, cells accumulated earlier in S-phase, and
at lOOnM Ara-C the cells were blocked at the G1/S
interface. Prednisolone blocks CEM-C7 cells in G,
phase of the cell cycle (Harmon et al., 1979), but
when Ara-C was added to cells during the final 24h
of a 48h incubation with steroid (protocol 1), the S-
phase blockage induced by Ara-C was virtually
identical to that observed in the absence of steroid
(data not shown). These results were similar to
those obtained with prednisolone and 6-
mercaptopurine-a combination which is also
antagonistic when used according to protocol
(Norman et al., 1978; Gledhill & Norman, 1981b).
Reversibility of the S-phase block induced hr
cytosine arabinoside
To investigate the reversibility of the Ara-C effect on
CEM-C7 cells, FMF patterns were obtained for
cells that had been exposed to Ara-C for 24h,
washed free of the drug, and then re-incubated in
drug-free medium. Data for 40nM Ara-C are given inSYNERGISTIC KILLING OF LYMPHOBLASTS 651
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Figure 1 DNA distribution in CEM-C7 cells treated with Ara-C for 24h. Cellular DNA content was
measured by flow microfluorimetry (FMF). Relative fluorescence intensity is proportional to the DNA
content of the cells. The first peak (channel no. 60) represents cells in G1 phase of the cell cycle with a diploid
DNA content. The second peak (channel no. 120) rep,esents cells in, G2 and M-phase which have a tetraploid
DNA content. Between the 2 peaks are cells in S-phase With inte'inediate amounts of DNA. Each profile is
the result of measurements on 104 cells. The FMF pattern for control cells (a) is compared with those for (b)
10nM (c) 20nM (d) 40nM (e) 50nM and (f) 100nM Ara-C. Cells were counted before and after treatment with
Ara-C and the inhibitory effect of Ara-C on cell growth was expressed as a percentage of the increase in cell
number in control culture. Cell growth was inhibited by 38% at 10nM, 61% at 20nM, 76% at 40nM, 80% at
5OnM and 94% at 100nM.
Figure 2. Two hours after the drug had been
removed there was some evidence of passage
through S-phase. Samples taken 5, 8 and 1lh after
washing demonstrated continued movement of cells
through S-phase and into cell division. Viability of
Ara-C treated cells, measured by nuclear pyknosis,
remained >90% throughout the period of the
experiment. The number of cells in mitosis was
decreased relative to control immediately after Ara-c
treatment, but increased to levels greater than
control at 8h and llh, thus confirming the results
obtained with FMF (Table I).
Interaction of glucocorticoids and cytosine
arabinoside
Protocol 2 was designed to determine whether or
Table I Viability and mitotic index of CEM-C7 cells
after treatment with Ara-C (40nM) and re-incubation in
drug-free medium
Time after removal ofAra-C
(a) (b) (c) (d) (e) (f)
Control Oh 2h 5h 8h llh
Mitotic
Cells (%) 2.3 0.8 1.0 3.4 5.0 4.2
Viable
Cells (%) 97.2 95.8 96.8 95.2 96.8 93.6
During the experiment described in Figure 2 samples
were wet-fixed and stained (see Methods) and analysed for
morphologically viable cells and for cells in mitosis.
Letters in parentheses refer to the FMF patterns in Figure
2.
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Figure 2 Reversibility of Ara-C-induced inhibition of DNA synthesis. CEM-C7 cells were treated with Ara-C
(40nM) for 24h. An aliquot was taken for DNA analysis by flow microfluorimetry, while other Ara-C treated
cells were washed and re-incubated in drug-free medium. The FMF pattern for control cells (a) is compared
with the pattern immediately after Ara-C treatment (b) and with patterns obtained (c) 2h (d) 5 h (e) 8 h and (f)
11 h after removal of the drug.
not the glucocorticoid-induced cell killing could be
increased by first blocking CEM-C7 cells in a state
where they were protected from the lethal effect of
glucocorticoid, removing the block, and then
exposing the partially synchronised cells to steroid.
Protocol 2 dose/response curves were produced by
treating CEM-C7 cells with a range of Ara-C
concentrations (5-100nM) for 24h, washing them
free of the drug, and then re-incubating in a
medium containing prednisolone (10-6M) for a
further 48 h. The predicted cell survival after
exposure to both drugs was taken to be the product
of the survival after each drug alone, SA.SB (Table
II). The dose/response curves from one such
protocol 2 experiment are shown in Figure 3. It was
found that the interaction of Ara-C and
prednisolone, when combined according to protocol
2. was synergistic over the whole range of
concentrations used.
The synergistic interaction was reproducible in 4
dose/response experiments, and the results of all
these experiments, together with results from Figure
5, are incorporated into Figure 4. The difference
between predicted and measured cell survival
Table II Terms used to describe the interaction between
glucocorticoids and cytosine arabinoside
SA
SB
SAB
SA.SB
=fraction of cells surviving treatment with
glucocorticoid
=fraction of cells surviving treatment with cytosine
arabinoside
=fraction of cells surviving treatment with both
drugs
=predicted cell survival after treatment with both
drugs
If both drugs act independently SAB=SA.SB and SAB
-SA.SB =0
If there is antagonism SAB>SA.SB and SAB -SA.SB will
be positive.
If there is synergism SAB<SA.SB and SAB -SA.SB will be
negative.
U)
4-
0
6
z
I
ISYNERGISTIC KILLING OF LYMPHOBLASTS 653
~itO
IE
('.A
f.
;: * ' . ,.:0 3
Figure 3 Dose/response curves for CEM-C7 cell
survival (measured by plating efficiency) after 24h
treatment with Ara-C alone (0) and for cells treated
with prednisolone (106M) after 24h prior exposure to
Ara-C (0). Each point is the mean (±s.e.) of 4-5 dishes,
using cells taken from 1 flask. The curves are
compared with the theoretical curve (-) calculated
from the cell survival after treatment with each drug
alone (see Table II).
(SAB-SA.SB) was greatest in conditions where the
predicted cell survival (SA.SB) was highest. The
slope of the regression line, however, indicates that
the number of cells found to survive the drug
combination was consistently about half that
predicted for all values of SA SB*
Effect of cytosine arabinoside on the time course of
steroid-induced cell killing
Prednisolone-induced cell killing was measured
during the 3 days following treatment of cells with
10nM Ara-C, a dose which was non-lethal when used
alone (SB= 1) but was found to be capable of
increasing the amount of cell killing in the presence
of steroid. Prior exposure to Ara-C increased cell
killing throughout the 3 days (Figure 5A), but the
shapes of the two curves in Figure 5A suggested
that the main effect of Ara-C occurred during the
first 24h of culture with steroid.
Previous work (Harmon et al., 1979) had shown
that there is a lag period of about 20h before
dexamethasone begins to reduce the cloning
efficiency of CEM-C7 cells, so the effect of prior
exposure to Ara-C (10nM) on the lag phase after
dexamethasone treatment was investigated in more
detail (Figure 5B). In this experiment, lOnM Ara-C
inhibited cell growth by about 86% but was again
non-lethal when used alone. The survival curves
show that prior exposure to 10nM Ara-C reduced the
lag period before cell killing in the presence of
steroid could be measured from about 18 h to about
12h, but it did not completely abolish the lag
phase.
Discussion
Cytosine arabinoside has proved to be of
considerable value in the treatment of leukaemia
(Rivera et al., 1980a, b; Keating et al., 1981; Early et
al., 1982) but, as with glucocorticoids, there is some
doubt as to the exact mechanism of its cytocidal
action. The nucleotide derivative, Ara-CTP, is a
potent inhibitor of DNA synthesis (Cozzarelli, 1977)
and Ara-C is specifically toxic to cells in S-phase of
the cell cycle (Bhuyan et al., 1973; Meyn et al.,
1980). There is evidence for blocking of DNA
synthesis by competitive inhibition of DNA
polymerase (Graham & Whitmore, 1970b) and by
chain termination after incorporation of Ara-CTP
into DNA (Momparler, 1972, 1974). Inhibition of
DNA synthesis alone does not necessarily result in
cell death (Graham & Whitmore, 1970a; Priesler et
al., 1979) but there is some evidence for a
relationship between the amount of Ara-C
incorporated into DNA and loss of clonogenicity by
lymphoid cells in vitro (Kufe et al., 1980; Major et
al., 1981). Inhibition of DNA synthesis by Ara-C
results in chromosome damage, and the extent of
this damage can also be correlated with cell killing
(Benedict et al., 1970; Karon et al., 1972; Moore,
1981; Jones et al., 1976). Woodcock et al. have
proposed that double replication of some DNA
segments following removal of the Ara-C block
causes the chromosome aberrations which lead to
abnormal segregation of chromatids at mitosis and
cell death (Woodcock et al., 1979; Woodcock &
Cooper, 1981).
Treatment of CEM-C7 cells in vitro with Ara-C
and prednisolone according to protocol 1, in which
both drugs were present during the final 24h of a
48h incubation with steroid, resulted in cell killing
which was less than predicted from the toxicity of
each drug alone (Gledhill & Norman, 1981b). The
antagonism was evident at Ara-C doses (-1OnM)
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Figure 4 Relationship between the protocol 2 interaction of Ara-C and glucocorticoids, expressed as SAB
-SA.SB, and the theoretical cell survival, SA.SB. The terms are defined in Table II. The values were derived
from a total of 5 dose/response and time-course experiments. The regression line has a correlation coefficient
of 0.847 (P<0.001).
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Figure 5 Time course of CEM-C7 cell survival (measured by plating efficiency) in the presence of (a)
prednisolone (10-6M) or (b) dexamethasone (10-6M). Cells were incubated with (0) or without (0) lOnM
Ara-C for the 24h before steroid treatment.
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that were capable of inhibiting cell growth but were
not lethal when used alone, suggesting that the
antagonism was due to modulation of steroid
potency by Ara-C.
Our working hypothesis for the mechanism of
protocol 1 antagonism proposes that Ara-C
reversibly blocks some CEM-C7 cells in S-phase of
the cell cycle, where they are protected from the
lethal effects of steroid. FMF patterns presented
above (Figure 1) have confirmed that treatment of
CEM-C7 cells with Ara-C causes accumulation of
cells in S-phase ofthe cell cycle. Low doses ofAra-C
(10-50nM) allowed entry of cells into S-phase but
inhibited completion ofS-phase, while 100nM Ara-C
blocked virtually all DNA synthesis. Similar
changes in FMF patterns according to Ara-c dose
have been observed with other cell systems (Fried et
al., 1981). Other data (not shown) also confirmed
the predominance of the Ara-C effects over those
induced by steroid. When Ara-C was removed from
the cultures and cells were reincubated in drug-free
medium there was a reversal of its effect on DNA
synthesis-the cells were able to complete S-phase
and enter mitosis (Figure 2).
Since the corollary to the hypothesis stated above
is that cells should be more steroid-sensitive in
phases of the cell cycle other than S-phase, an
attempt was made to test this prediction by altering
the timing of drug addition so that steroid was
added to cells that had been exposed to Ara-C for
the previous 24h (protocol 2). Under these
conditions the interaction observed became one of
synergism rather than antagonism (Figure 3).
After removal of Ara-C by washing, a period of
about 5h elapsed before any cells reached mitosis.
Analysis 8 h and 11 h after removal of Ara-C
confirmed that a greater than normal number of
cells had entered mitosis, and there was then an
increase in the number of cells in G1 (Figure 2).
Thus, the time required for synchronised cells to
reach G1 phase corresponds with the time at which
a fraction of the pre-treated cells are killed more
rapidly than control cells (between 12h and 20h see
Figure SB), suggesting that lysis of synchronised
cells is induced in the subsequent G1 phase.
This explanation would agree with other evidence
that glucocorticoid-induced cell death occurs in G1
phase: (a) administration of glucocorticoids in vivo
resulted in a decrease in the number of dividing
leukaemic cells that were able to enter S-phase
(Lampkin et al., 1969; Ernst & Killman, 1970); (b)
Glucocorticoids inhibited progress from G1 into S
in lymphocytes stimulated in vitro with PHA
(Sloman & Bell, 1980) and had similar effects on
other cells lines in vivo (Braunschweiser & Schiffer,
1979) aind in ritro (Bakke & Eilk-Nes, 1981); (c)
Treatment of CEM-C7 cells with glucocorticoids
caused an irreversible increase in the number of
cells in G1 which were unable to form clones
(Harmon et al., 1979); (d) Glucocorticoids also kill
non-dividing thymocytes (Munck et al., 1979) and
lymphocytes from patients with chronic
lymphocytic leukaemia (Galili et al., 1982) which
are in prolonged G1 or Go states.
What is not yet clear, however, is whether the
entire process of steroid killing necessarily occurs in
Gl, or whether an effect of steroid which is
initiated in some other phase of the cell cycle
eventually results in cell death when steroid is
present during G1 phase. Since the doubling time of
the cells (-20h) is approximately equal to the time
elapsed before steroid induces loss of cloning
efficiency, the former mechanism would imply that
a single G1 phase is insufficient for steroids to exert
their effects. The synergism observed with Ara-C
may indicate that the latter mechanism is correct,
and the process of steroid killing is initiated during,
or soon after, S-phase.
The data currently available for interactions
between Ara-C and glucocorticoids are compatible
with the hypothesis that the steroids are cell cycle
specific. There are, however, other explanations
that also fit the data. Synergism would occur in
protocol 2 if the presence of steroid could
potentiate minor damage caused by Ara-C to a
degree which results in cell death. Such a
mechanism would be similar to the synergism
between glucocorticoids and various alkylating
agents which has been observed in cells which are
not lysed by glu,cocorticoids (Harrap et al., 1977;
Shepherd & Harrap, 1982; Tew et al., 1982). Since
both Ara-C and the alkylating agents are known to
damage DNA, it is possible that glucocorticoids
interfere with DNA repair mechanisms and so
diminish the ability of cells to recover from
exposure to these drugs.
The results demonstrating antagonism described
previously (Gledhill & Norman, 1981b), together
with the synergistic interactions described in this
paper, suggest that the effectiveness of a
combination of Ara-C and prednisolone in
leukaemia therapy could be influenced by the
timing of drug administration. It is now important
to determine whether or not the synergistic
interactions can be reproduced and enhanced in
vivo.
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